20-F: China SXT Pharmaceuticals Reports Widening Losses Amid Revenue Decline and Internal Control Deficiencies

China SXT Pharmaceuticals, Inc. reported a 10% revenue decrease and a 7% increase in net loss for the fiscal year ended March 31, 2025, alongside disclosed material weaknesses in its internal financial reporting controls.

Summary

• Revenues decreased by 10% to $1,740,907 for the fiscal year ended March 31, 2025, from $1,928,497 in the prior year.
• Net loss increased by 7% to $3,303,652 for the fiscal year ended March 31, 2025, compared to $3,098,532 in the previous year.
• Gross profit declined by 34% to $367,427 for the fiscal year ended March 31, 2025, with gross margin falling to 21.1% from 28.7% in the prior year.
• The decrease in gross margin is primarily attributed to a significant decrease in sales of higher-margin Advanced TCMP products and an increased proportion of lower-margin Regular TCMP sales.
• Selling and marketing expenses decreased by 33% to $289,859, mainly due to reduced market development and advertising fees.
• General and administrative expenses increased by 5% to $2,758,047, driven by higher credit loss for accounts receivable and a $1,006,052 impairment loss for long-term deposit.
• Net cash used in operating activities increased to $2,345,333 for the fiscal year ended March 31, 2025, from $1,928,053 in the prior year.
• The company raised $8,399,153 from financing activities in fiscal year 2025, primarily through related party proceeds, convertible notes, and share purchase agreements.
• As of March 31, 2025, cash and cash equivalents and restricted cash stood at $18,129,432, with total current assets of $21,296,491 and total current liabilities of $6,012,063.
• The company's accumulated deficits reached $28,015,317 as of March 31, 2025.
• Management concluded that internal control over financial reporting was not effective as of March 31, 2025, citing inadequate accounting personnel and segregation of duties.
• The company continues to operate through a Variable Interest Entity (VIE) structure in China, which is subject to significant regulatory and legal uncertainties in the PRC.

Sentiment

Score: 2

Explanation: The company exhibits significant financial deterioration with declining revenues, increasing net losses, and a worsening gross margin. The disclosed material weaknesses in internal controls over financial reporting are a major concern, indicating a lack of reliability in financial reporting. Heavy reliance on dilutive capital raises and high customer concentration further contribute to a highly negative outlook.

Positives

• Net loss decreased by 48% from $5,934,772 in fiscal year 2023 to $3,098,532 in fiscal year 2024, indicating some improvement in cost control during that period.
• The company successfully raised $8,399,153 in net cash from financing activities in fiscal year 2025, significantly improving its cash and cash equivalents balance to $18,129,432.
• Regular TCMP product revenue increased by 53% to $1,442,466 in fiscal year 2025, indicating increased market demand for this product segment.
• The company has a recognized brand name, Suxuantang, with over 270 years of history and numerous local government awards, providing a competitive advantage in the TCM industry.
• The company possesses complete permits to produce Advanced TCMP products, including Directly-Oral and After-Soaking-Oral TCMPs, which offer convenience to customers by not requiring decoction.
• Strong research and development capabilities are highlighted, with 28 utility model and invention patents, and ongoing R&D efforts in advanced TCMP processing methods and quality standards, including electron beam sterilization and dust-sucking thermostatic pulverizing technique.
• The company has an experienced leadership team with extensive industry experience in TCM research, development, manufacturing, and commercialization.

Negatives

• Total revenues decreased by 10% to $1,740,907 for the fiscal year ended March 31, 2025, compared to $1,928,497 in the prior year.
• Net loss increased by 7% to $3,303,652 for the fiscal year ended March 31, 2025, from $3,098,532 in the previous year.
• Gross profit decreased by 34% to $367,427 for the fiscal year ended March 31, 2025, and gross margin declined to 21.1% from 28.7%.
• Revenue from Advanced TCMP products, which have a relatively high margin, decreased significantly by 73% to $258,416 in fiscal year 2025.
• The company discontinued cooperation with major clients in the sales of Fine TCMP and will not develop or sell these products in the future, leading to a nearly 100% revenue decrease in this segment in fiscal year 2024.
• General and administrative expenses increased due to higher credit loss for accounts receivable and a $1,006,052 impairment loss for long-term deposit in fiscal year 2025.
• Net cash used in operating activities increased by $417,280 to $2,345,333 in fiscal year 2025, indicating a worsening operational cash burn.
• The company had accumulated deficits of $28,015,317 as of March 31, 2025, reflecting a history of losses.
• Management concluded that internal control over financial reporting was not effective as of March 31, 2025, due to inadequate accounting personnel and insufficient segregation of duties.
• The company is highly dependent on a small number of customers, with one significant customer accounting for 68.72% of total revenue in fiscal year 2025, posing a substantial concentration risk.
• A long-term deposit of $8,268,221 was partially offset by related party payables, but $1,000,451 was deemed unrecoverable and impaired in fiscal year 2025.
• The company has relied heavily on financing transactions, including multiple convertible notes and share purchase agreements, which have led to significant share dilution through reverse stock splits and warrant exercises.

Risks

• Risks related to natural disasters, adverse weather, pandemic outbreaks (e.g., COVID-19), terrorist acts, and global political events could adversely affect business and financial performance.
• Significant business lines have a limited operating history, making future prospects and results of operations difficult to evaluate.
• Dependence on a small number of customers (one customer accounted for 68.72% of total revenue in FY2025) could adversely affect business or results of operations if contracts are not renewed.
• Business requires numerous permits and licenses, and any failure to maintain or renew them, or pass GMP compliance inspections, could materially affect operations.
• Disruptions in the supply chain of raw materials and products could adversely impact production and delivery.
• Price control regulations in the PRC may decrease profitability by setting price ceilings without limiting costs.
• TCMP products may be replaced by other medicines or removed from the PRC's insurance catalogue, leading to revenue loss.
• Adverse publicity associated with products, ingredients, or network marketing programs could harm financial condition and operating results.
• Reliance on VIE Agreements for business operations in China may not be as effective in providing operational control or benefits as direct ownership, and these agreements have not been tested in a Chinese court.
• Contractual arrangements with the VIE may be subject to scrutiny by PRC tax authorities, potentially leading to additional taxes (e.g., transfer pricing adjustments, gift tax on equity transfers).
• Uncertainty exists regarding the need for China Securities Regulatory Commission (CSRC) and other PRC authorities' approval for overseas listings, which could lead to sanctions or hinder ability to offer securities.
• PRC laws and regulations governing current business operations are sometimes vague and uncertain, and subject to policy changes, affecting enforceability of contractual arrangements.
• Uncertainties with the PRC Foreign Investment Law may impact the viability of the current corporate structure and business operations, potentially classifying contractual arrangements as foreign investment.
• Reliance on dividend payments from the VIE is subject to restrictions under PRC laws, including statutory reserve requirements and debt covenants.
• Exercising the option to acquire equity ownership of Taizhou Suxuantang may subject the company to certain limitations and substantial tax costs.
• The market price for ordinary shares may be volatile due to various factors, including perception of U.S.-listed Chinese companies and sales by existing shareholders.
• Failure to establish and maintain proper internal financial reporting controls could impair the ability to produce accurate financial statements or comply with regulations, potentially leading to delisting.
• As a foreign private issuer, the company is not subject to certain U.S. securities law disclosure requirements and may adopt home country corporate governance practices that offer less protection to shareholders.
• Loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• The company does not intend to pay dividends for the foreseeable future, meaning shareholders may only receive a return through share price appreciation.
• Public disclosure obligations may put the company at a disadvantage compared to private competitors in China.
• A sale or perceived sale of a substantial number of shares may cause the price of ordinary shares to decline.
• Joint statements by the SEC and PCAOB, rule changes by Nasdaq, and the HFCA Act could add uncertainties to offerings and potentially lead to delisting if auditors are not fully inspected.
• Changes in China's economic, political, or social conditions, and significant government authority to intervene, could materially affect business operations and share value.
• Recent greater oversight by the Cyberspace Administration of China (CAC) over data security, particularly for companies seeking foreign listings, could adversely impact business.
• Uncertainties with the Chinese legal system, including enforcement of laws and sudden changes, could limit legal protections.
• Difficulty in enforcing rights under VIE Agreements in PRC courts due to the less developed legal environment.
• Difficulty for overseas shareholders and/or regulators to conduct investigations or collect evidence within China due to PRC laws.
• Exposure to foreign currency exchange rate fluctuations (RMB to USD) could adversely affect business, results of operations, and financial condition.
• PRC regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent the use of financing proceeds.
• Labor disputes could significantly affect operations and expansion plans.
• Classification as a PRC Resident Enterprise could result in unfavorable tax consequences, including a 25% enterprise income tax on worldwide income and potential withholding tax on dividends/gains for non-PRC stockholders.
• Exposure to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption law.
• Governmental control of currency conversion may affect the value of investment and ability to pay dividends in foreign currencies.
• Bankruptcy or dissolution proceedings of PRC subsidiaries could materially and adversely affect business operations.
• The company does not carry product liability insurance, business interruption insurance, or key-man insurance, increasing financial exposure to claims or disruptions.

Future Outlook

The company plans to increase efforts in cooperation with universities, research institutes, and R&D agents on joint R&D projects involving TCMP processing methods and quality standards, as well as researcher training. It intends to continue focusing on developing new Advanced TCMP products and expects to introduce new products at a steady pace to strengthen its market leadership in Directly-Oral and After-Soaking-Oral-TCMPs. The company also plans to expand its distribution network within the PRC and eventually to international markets by partnering with international pharmaceutical companies.

Management Comments

• Management believes that the innovative feature of their Directly-Oral-TCMP and After-Soaking-Oral-TCMP products, which do not require decoction, provides a competitive edge in the market.
• Management believes the company is well-positioned in a steadily growing industry in one of the fastest-growing economies in the world.
• Management believes their R&D team holds a leading position in the R&D field of Advanced TCMP products based on market analysis.
• Management believes the company is well-positioned to compete in the fast-developing market with its well-recognized Suxuangtang brand, diversified product portfolio, proven R&D and in-licensing capabilities, established sales and marketing network, management experience, and favorable cost structure.
• Management believes that they maintain a good working relationship with their employees and have not experienced any major labor disputes.
• Management considers their insurance coverage to be sufficient for their business operations in China.
• Management considers the possibility of PRC regulatory authorities finding the VIE structure in violation of PRC law to be remote.
• Management is committed to improving internal controls over financial reporting and will undertake consistent improvements or enhancements on an ongoing basis, estimating completion by the end of the current year without material costs.

Industry Context

The company operates in the Traditional Chinese Medicine (TCM) pieces (TCMP) industry in China, a segment that has experienced rapid growth due to favorable government policies. Unlike Western medicine, TCMP products are exempt from rigorous clinical trials before commercialization. The company differentiates itself by offering innovative 'ready-to-use' TCMP products (Directly-Oral and After-Soaking-Oral) that do not require complex decoction, a feature that provides a competitive edge. The industry is highly regulated by the NMPA, with strict GMP standards and specific requirements for TCMP manufacturing. Competition is intense, with many established players, some with greater financial and marketing resources. The company aims to leverage its historical brand recognition and R&D capabilities to compete in this evolving market.

Comparison to Industry Standards

• The company's gross margin of 21.1% in FY2025 is lower than its own previous year's 28.7%, indicating a decline in profitability per unit of revenue, potentially below industry averages for specialized pharmaceutical products.
• The company's dependence on a single customer for 68.72% of its revenue in FY2025 is a significant concentration risk, which is generally considered a deviation from healthy industry diversification standards.
• The company's lack of product liability insurance, business interruption insurance, and key-man insurance is a notable gap compared to standard risk management practices in the global pharmaceutical industry, leaving it exposed to significant uninsured liabilities.
• The company's internal control over financial reporting was deemed 'not effective' due to inadequate accounting personnel and segregation of duties, which falls short of the robust internal control standards expected of publicly traded companies, especially those subject to Sarbanes-Oxley Act requirements.
• While the company highlights its 'national leading position' in Advanced TCMP R&D based on its market analysis of 11 products, specific comparative metrics against competitors like Kangmei, CTCM, and Xiangxue are not provided to substantiate this claim against broader industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• May from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• Revenues generated from related parties totaled $4,301 in FY2025, $27,760 in FY2024, and $33,621 in FY2023.
• The company made no advances to related parties in FY2025, but made $2,205,254 in FY2024 and $628,911 in FY2023.
• The company made no repayments to related parties in FY2025, but made $1,727,418 in FY2024 and $2,197,555 in FY2023.
• Non-cash settlement between accounts receivable from related parties and due to related parties was $Nil in FY2025, $1,235,290 in FY2024, and $1,263,993 in FY2023.
• Non-cash settlement between due from related parties and due to related parties was $8,993,443 in FY2025, $6,080,971 in FY2024, and $4,051,569 in FY2023.
• A non-cash settlement of $7,267,770 occurred in FY2025 between long-term deposit and due to related parties.
• The company borrowed $90,024 from Jun Zheng (a director) in FY2024, with no fixed term and a 6% interest rate.
• The company has a free 10-year lease agreement for office and warehouse space (3,627 sqm) with Jiangsu Health Pharmaceutical Investment Co., Ltd., a related party, entered into on January 1, 2018.
• Taizhou Suxuantang signed a financial guarantee agreement with Jiangsu Changjiang Commercial Bank for Taizhou Jiutian Pharmaceutical Co. Ltd. (a related party) for $303,168 (RMB 2,200,000) for three years, expiring April 22, 2027.
• Taizhou Suxuantang previously signed a financial guarantee agreement for Jianping Zhou (a related party, now deceased) for $799,261 (RMB 5,800,000) for an unlimited period; Taizhou Jiutian Pharmaceutical Co. Ltd. has since taken over this obligation.

Stakeholder Impact

• Shareholders face significant dilution risk due to multiple recent and ongoing capital raises involving issuance of ordinary shares and warrants, compounded by multiple reverse stock splits.
• Shareholders are unlikely to receive dividends in the foreseeable future as the company intends to retain earnings for business expansion.
• Shareholders are exposed to high investment risk due to the company's declining revenues, increasing net losses, and accumulated deficits.
• Shareholders' interests may be less protected compared to U.S. domestic issuers due to the company's adoption of British Virgin Islands corporate governance practices in lieu of certain NASDAQ standards.
• Employees are covered by various government statutory employee benefit plans, including social insurance and housing provident fund, and the company reports good working relationships with no major labor disputes.
• Customers, particularly the single significant customer accounting for 68.72% of FY2025 revenue, are critical to the company's financial stability, and loss of such customers would severely impact the business.
• Suppliers face concentration risk as the company relies on a few major suppliers, and disruptions could impact the company's ability to produce products.
• Creditors, particularly holders of convertible notes, have seen their debt converted into equity, and the company has engaged in significant borrowing from banks and individuals, indicating reliance on debt financing.

Next Steps

• Increase efforts in cooperation with universities, research institutes, and R&D agents on joint R&D projects involving TCMP processing methods and quality standards.
• Increase training for researchers.
• Focus on developing new Advanced TCMP products.
• Introduce new products at a steady pace to strengthen branded market leadership position in Directly-Oral and After-Soaking-Oral-TCMPs.
• Promote the efficacy and safety profiles of all Advanced TCMP products to physicians at hospitals and clinics through sales force, independent distributors, and educational physician conferences and seminars.
• Expand the distribution network within the PRC to increase market penetration.
• Broaden marketing efforts outside of major cities in the PRC and increase market penetration in cities and rural areas.
• Over the long term, expand presence beyond the PRC to international markets by partnering with international pharmaceutical companies.
• Remediate material weaknesses in internal control over financial reporting by engaging bilingual accounting consultants, providing US GAAP training to in-house staff, retaining additional accounting personnel, enhancing internal finance and accounting organizational structure, strengthening direct management oversight of transactions, and developing internal control training.

Key Dates

Recommendation

The company's financial performance is deteriorating, marked by declining revenues, increasing net losses, and a significant drop in gross margin. The disclosed material weaknesses in internal control over financial reporting raise serious concerns about the reliability of its financial statements and overall operational integrity. The heavy reliance on a single customer for a substantial portion of revenue presents a critical concentration risk. Furthermore, the continuous and highly dilutive capital raises, including multiple convertible notes and warrant exercises, indicate persistent liquidity challenges and will likely continue to erode shareholder value. The inherent risks associated with the VIE structure and the uncertain regulatory environment in China add another layer of significant risk. These factors collectively point to a highly unstable and risky investment.

Keywords

Traditional Chinese Medicine, TCMP, Pharmaceuticals, China, SEC Filing, Form 20-F, VIE Structure, Financial Results, Corporate Governance, Risk Factors, Capital Raise, Reverse Stock Split, Internal Controls, Nasdaq